Company: GVH
Filing Date: 2025-06-10
Form Type: F-1/A
Source: 0001213900-25-052766
Chunk: 65

Company: Globavend Holdings Ltd
Filing Date: 2025-06-10
Form: F-1/A
Chunk 65
---
 returned
under any circumstances whether during or after this Offering.

Lack of voting rights.

Holders of the Warrants
will not have the same voting rights as those associated with our Ordinary Shares and may have no voting rights with respect to the shares
underlying the Warrants until such Ordinary Shares are acquired upon exercise of the Warrants. As a result, if such holders do not exercise
their Warrants, they will not have any influence over matters requiring shareholders’ approval during the period they hold the
Warrants.

<div align='center'>24</div>

Exercise and conversion dilution.

The exercise of the Warrants
will increase the number of Ordinary Shares issued and outstanding, which will dilute the ownership interests of existing shareholders.
The amount of dilution, or the reduction in value to existing shares of Ordinary Shares, is determined by the amount of shares ultimately
obtained upon the exercise of the Warrants relative to the number of shares of Ordinary Shares outstanding at the time of exercise.

If the Units are deemed to be non-compliant with Nasdaq rules, we may be required to amend the terms of the Warrants, and could be subject to delisting.

While the Company believes
the Units (and the underlying securities) are compliant with the rules and regulations of Nasdaq, the Company cannot provide any
guarantee that the Units, or, based on the Units, this Offering are compliant with such rules and regulations, and Nasdaq may require
amendment to the terms of the Warrants in order to comply with its rules and regulations including terms that are less favorable to the
investors in this Offering. Additionally, if we are unable to adequately address Nasdaq rules, our Ordinary Shares could be subject to
delisting from Nasdaq, which would materially adversely affect our liquidity and investors’ investment in our securities.

If the holders of the Series B Warrants elect to exercise such warrants using the zero exercise price option, we may not receive any additional funds and our Shareholders will suffer substantial dilution.

The Series B Warrants
contain a zero exercise price provision which provides the holders the right, at their option, to receive a number of Ordinary Shares
equal to the product of (a) the number of shares that would be issuable upon exercise of the Series B Warrant in accordance
with the terms of such warrant if such exercise were by means of a cash exercise rather than a cashless exercise and (b) the quotient
obtained by dividing (i) the exercise price minus